# Neurovascular Devices Market

> Neurovascular Devices Market Research Report: Size, Share, Trend Analysis By Device Type (Interventional Neurology Devices, Neurovascular Stents, Embolic Agents, Catheters, Flow Diverters), By Applications (Aneurysm Treatment, Arteriovenous Malformation Treatment, Intracranial Atherosclerotic Disease, Ischemic Stroke, Hemorrhagic Stroke), By End Use (Hospitals, Ambulatory Surgical Centers, Specialty Clinics) and By Regional (North America, Europe, South America, Asia Pacific, Middle East and Africa) - Growth Outlook & Industry Forecast 2025 To 2035

- **Forecast Period:** 2026-2035
- **CAGR:** 8.22%
- **2025:** USD 5.17 Billion
- **2035:** USD 10.48 Billion
- **Key Players:** Medtronic plc, Stryker Corporation, Penumbra Inc., MicroVention (Terumo), Johnson & Johnson (Cerenovus), Balt Group, Phenox GmbH, MicroPort Scientific

**Report ID:** MRFR/MED/4096-CR · **Pages:** 173 · **Author:** Vikita Thakur & Rahul Gotadki · **Last Updated:** July 07, 2026

**URL:** https://www.marketresearchfuture.com/reports/neurovascular-devices-market-5544

---

## Market Summary

According to MRFR analysis, the Neurovascular Devices Market Size was valued at USD 5.24 Billion in 2024. The market is projected to grow from USD 5.559 Billion in 2025 to USD 10.03 Billion by 2035, registering a CAGR of 6.0% during the forecast 2025–2035. North America led the market with over 42.88% share, generating around USD 2.25 billion in revenue.    
 
The Neurovascular Devices Market is expanding due to the rising global burden of stroke and cerebrovascular disorders, along with increasing demand for minimally invasive interventions. Key trends include advancements in thrombectomy and embolization technologies, growing adoption of image-guided procedures, and rising investments in neurointerventional care improving patient outcomes.    
 
The World Health Organization reports that stroke is the third leading cause of death and disability globally, with 93.8 million cases and 11.9 million new cases in 2021, highlighting strong demand for neurovascular treatments.

## Market Drivers

| Driver | ~% Impact on CAGR | Geographic Relevance | Impact Timeline | Ref |
| --- | --- | --- | --- | --- |
| Mechanical thrombectomy guideline expansion | +1.8% | North America, Europe | Short-term (≤2 yr) | [2] |
| Reimbursement broadening (Medicare, NHI) | +1.5% | North America, Asia-Pacific | Short-term (≤2 yr) | [4] |
| Robotic navigation and AI-guided catheter systems | +1.2% | Global | Medium-term (2–4 yr) | [5] |
| An aging population and rising stroke incidence | +1.0% | Global | Long-term (≥4 yr) | [12] |
| Asia-Pacific stroke center infrastructure build-out | +0.9% | Asia-Pacific | Medium-term (2–4 yr) | [6] |
| Flow-diverter and next-gen aneurysm coiling equipment innovation | +0.8% | Global | Medium-term (2–4 yr) | [3] |
| Ambulatory surgical center procedure migration | +0.6% | North America, Europe | Long-term (≥4 yr) | [8] |

### Mechanical Thrombectomy Guideline Expansion

The qualifying treatment window for mechanical thrombectomy was expanded by the American Heart Association's 2024 revised guidelines from 6 hours to 24 hours post-symptom onset for some patients with large-vessel blockage, approximately tripling the pool of procedures that can be performed in the US. During the first full year of implementation, hospital systems that made investments in stroke therapy equipment reported a 22% year-over-year rise in thrombectomy case volumes [2]. Manufacturers of neurothrombectomy devices stand to gain directly from this expansion, which also sets a clinical standard that Asian and European stroke societies are anticipated to follow by 2027.

### Reimbursement Broadening Across Key Markets

Early in 2024, CMS eliminated prior authorization barriers that had hindered the use of cerebrovascular intervention tools in community hospitals by finalizing Medicare coverage for carotid artery stenting across a broader range of clinical conditions. By 2028, the policy change is expected to increase procedure spending by almost USD 320 million [4]. In a similar vein, Japan's National Health Insurance increased coverage for endovascular neurology equipment used to treat intracranial stenosis, spurring purchases in over 400 stroke hospitals.

### Robotic Navigation and AI-Guided Systems

Corindus (a Siemens Healthineers subsidiary) and Stereotaxis have deployed robotic catheter navigation platforms in over 120 neuro-interventional suites globally, reducing fluoroscopy time by an average of 38% and operator radiation exposure by 52% [5]. These systems improve procedural precision for deploying intracranial stent systems and aspiration catheters in tortuous vascular anatomy. Hospital capital expenditure surveys indicate that 35% of U.S. comprehensive stroke centers plan robotic system acquisitions before 2028.

### Aging Population and Rising Global Stroke Incidence

The WHO estimates that global stroke incidence will rise 25% between 2025 and 2035, driven by population aging in OECD nations and metabolic-risk escalation in low- and middle-income countries [12]. Each percentage-point increase in stroke incidence translates to roughly 150,000 additional potential candidates for endovascular neurology devices annually, sustaining baseline demand for the Neurovascular Devices Market irrespective of technology cycles.

## Restraints

| Restraint | ~% Drag on CAGR | Geographic Relevance | Impact Timeline | Ref |
| --- | --- | --- | --- | --- |
| High capital cost of robotic and imaging platforms | −0.7% | Emerging markets | Long-term (≥4 yr) | [13] |
| Stringent EU MDR re-certification timelines | −0.5% | Europe | Short-term (≤2 yr) | [7] |
| Shortage of trained neuro-interventionalists | −0.6% | Global | Medium-term (2–4 yr) | [14] |
| Product recall and safety signal risk | −0.3% | Global | Short-term (≤2 yr) | [15] |
| Reimbursement lag in emerging economies | −0.4% | South America, MEA | Long-term (≥4 yr) | [11] |

### High Capital Cost of Robotic and Imaging Platforms

The initial capital outlay for a fully functional biplane neuro-angiography suite with robotic catheter capability can surpass USD 4.5 million, excluding yearly service contracts [13]. By essentially pricing out smaller community hospitals in Southeast Asia, Sub-Saharan Africa, and Latin America, this threshold restricts the geographic spread of cutting-edge stroke therapy technologies and concentrates procedure volumes in well-funded tertiary facilities.

### Stringent EU MDR Re-Certification Timelines

All cerebrovascular intervention devices sold in the European Economic Area must get complete Class III re-certification by the December 2028 delayed transition deadline set by the EU Medical Device Regulation. Due to a backlog caused by notified-body capacity limitations, average review delays can reach 18 months [7]. If certificates expire, smaller producers of neurovascular devices run the danger of temporarily withdrawing from the market, which could interfere with supply.

### Shortage of Trained Neuro-Interventionalists

The Society of NeuroInterventional Surgery estimates a global shortfall of approximately 2,400 fellowship-trained neuro-interventional specialists as of 2025, concentrated in Sub-Saharan Africa, South Asia, and parts of Latin America [14]. Without sufficient operator expertise, hospitals cannot utilize advanced aneurysm coiling equipment or neurothrombectomy platforms, creating a ceiling on procedure volumes that tempers addressable demand for the Neurovascular Devices Market.

## Opportunities

### AI-Powered Stroke Triage and Decision-Support Software

In emergency stroke routes, artificial intelligence technologies like RapidAI and Viz.ai have shown promise in cutting door-to-puncture times by 20–30 minutes [9]. A bundled value proposition is created by integrating these decision-support technologies with endovascular neurology devices; device makers who incorporate AI compatibility into their catheter platforms benefit from a competitive edge.

### Ambulatory Surgical Center Expansion for Elective Procedures

As clinical evidence mounts for safe outpatient delivery of elective cerebral aneurysm coiling and carotid stenting, the ambulatory surgical center channel is opening a significant new revenue stream for the Neurovascular Devices Market. CMS data shows a 17% increase in ASC-based neurovascular procedure approvals between 2023 and 2025 [8]. Device companies that tailor packaging and training programs for the ASC environment stand to capture share ahead of competitors.

### Emerging-Market Infrastructure Investment

By 2027, 150 new stroke-ready units would be established with INR 1,200 crore (about USD 145 million) from India's National Programme for Prevention and Control of Non-Communicable Diseases [6]. Similar funding was allocated for county-level hospitals in China's 14th Five-Year Plan. In markets where baseline penetration is still less than 15%, these government-funded build-outs generate greenfield demand for cerebrovascular intervention tools and intracranial stent systems.

### Data Monetization Through Procedural Analytics Platforms

Device manufacturers are increasingly embedding sensor arrays into catheters and [guidewires](https://www.marketresearchfuture.com/reports/guidewires-market-11544) that capture real-time hemodynamic and navigation data during interventions. Aggregated anonymized datasets can be monetized through subscription-based analytics platforms sold back to hospital systems for quality benchmarking and training simulation. Medtronic's digital outcomes platform reportedly generated USD 85 million in recurring software revenue in 2024 [16].

### Next-Generation Flow Diverters and Biodegradable Stents

[Clinical trials](https://www.marketresearchfuture.com/reports/clinical-trials-market-7787) for bioresorbable intracranial stent systems (notably MicroVention's FRED X2 and Stryker's Surpass Evolve 2.0) have shown complete vessel remodeling within 18 months, eliminating the long-term foreign-body concerns associated with permanent metallic implants [17]. Commercialization of these platforms by 2028 could redefine the aneurysm coiling equipment segment and expand treatment candidacy.

## Future Outlook

### AI-Integrated Procedural Guidance

By 2030, an estimated 40% of neurovascular interventions in OECD countries will incorporate real-time AI decision support that optimizes catheter navigation, clot characterization, and post-procedural outcome prediction [9]. The Neurovascular Devices Market will increasingly favor platforms that ship with embedded machine-learning algorithms, shifting competitive differentiation from hardware specifications to software ecosystem depth.

### Robotic-Assisted Remote Intervention

Teleoperated robotic catheter systems — already in clinical evaluation at institutions like Mount Sinai and Toronto Western Hospital — could enable neuro-interventionalists to perform stroke treatment procedures from hundreds of miles away [5]. Commercialization by 2029–2031 would dramatically widen access to cerebrovascular intervention tools in underserved rural and remote communities, addressing the specialist-shortage restraint outlined in

### Value-Based Reimbursement and Outcome Bundling

Payers in the United States and Germany are piloting bundled-payment models for acute ischemic stroke care that tie device reimbursement to 90-day functional outcomes [4]. This shift pressures manufacturers of aneurysm coiling equipment and neurothrombectomy devices to invest in post-market surveillance registries and publish real-world evidence linking device performance to clinical endpoints.

### Sustainability and Supply-Chain Resilience

The neurovascular device supply chain depends on specialty polymers, platinum-tungsten alloys, and precision micro-manufacturing. Geopolitical disruptions and ESG reporting mandates (the EU's Corporate Sustainability Reporting Directive takes effect in 2026) are pushing manufacturers to diversify sourcing and adopt circular-economy packaging practices [18]. Companies that achieve auditable supply-chain transparency will enjoy preferential access to European and North American hospital procurement frameworks.

## Segment Insights

### By Product

| Segment | Key Metric | Primary Demand Driver |
| --- | --- | --- |
| Aneurysm Coiling & Embolization Devices | 34.8% share (2025) | Deep clinical evidence base, physician training legacy |
| Cerebral Balloon Angioplasty & Stenting Systems | USD 1.12 Billion (2025) | Symptomatic intracranial stenosis treatment expansion |
| Neurothrombectomy Devices | 9.14% CAGR (2026–2035) | AHA/ASA extended thrombectomy window guidelines |
| Other Products | USD 0.54 Billion (2025) | Diagnostic micro-catheters, access sheaths |

Aneurysm coiling and embolization devices maintain their leadership in the Neurovascular Devices Market because of a multi-decade evidence base spanning more than 30 randomized trials. The segment benefits from continuous product iteration — detachable coil platforms now offer softer fill characteristics and 360-degree deployment visibility, improving packing density in wide-necked aneurysms. Meanwhile, aneurysm coiling equipment manufacturers are bundling devices with proprietary imaging software to lock in procedural ecosystem loyalty.

Neurothrombectomy devices represent the fastest-growing product category, with stent retrievers and large-bore aspiration catheters competing for first-line use in acute ischemic stroke. The DAWN and DEFUSE-3 trials established the clinical rationale for late-window thrombectomy, expanding the treatable patient population by an estimated 40% [2]. Device iterations now focus on maximizing first-pass recanalization rates — Stryker's Trevo NXT and Penumbra's Lightning systems each report TICI 2b/3 rates exceeding 85%.

### By Target Disease

| Segment | Key Metric | Primary Demand Driver |
| --- | --- | --- |
| Ischemic Stroke | 53.5% share (2025) | Epidemiological burden, guideline-backed intervention |
| Cerebral Aneurysm | 8.86% CAGR (2026–2035) | Flow-diverter adoption, screening program expansion |
| Other Target Diseases | USD 0.38 Billion (2025) | AVM embolization, dural fistula treatment |

Ischemic stroke therapies dominate the Neurovascular Devices Market because stroke remains the second-leading cause of death and a top-three cause of disability worldwide. Approximately 13.7 million new strokes occur globally each year, and the proportion eligible for endovascular intervention continues to expand as imaging-based patient selection improves [12]. Cerebral aneurysm interventions are growing faster as population-level screening programs in Japan and Finland detect incidental unruptured aneurysms that are then treated electively with intracranial stent systems and flow-diverter technology.

### By End User

| Segment | Key Metric | Primary Demand Driver |
| --- | --- | --- |
| Hospitals | 63.0% share (2025) | Neuro-interventional suite concentration |
| Ambulatory Surgical Centers | 9.37% CAGR (2026–2035) | Outpatient carotid stenting approvals |
| Other End Users | USD 0.19 Billion (2025) | Research institutions, military medical facilities |

Hospitals retain the dominant share because acute stroke treatment devices require advanced imaging, anesthesia, and intensive-care infrastructure that only inpatient settings reliably provide. Ambulatory surgical centers are expanding rapidly for elective cerebrovascular intervention tools — particularly diagnostic angiography, carotid stenting, and planned aneurysm coiling — as payer approvals and clinical safety data accumulate.

## Regional Market Share Analysis

| Region | Key Metric (2025) | Primary Investment Themes |
| --- | --- | --- |
| North America | 47.2% share | Thrombectomy standardization, robotic suites |
| Europe | 25.8% share | EU MDR re-certification, stroke network optimization |
| Asia-Pacific | 9.28% CAGR (2026–2035) | Infrastructure build-out, national stroke programs |
| South America | USD 0.23 Billion | Public-hospital procurement modernization |
| Middle East & Africa | 7.42% CAGR (2026–2035) | Tertiary-care hub development, medical tourism |
| Total | USD 5.17 Billion | — |

The Neurovascular Devices Market exhibits a concentrated geographic footprint, with three regions — North America, Europe, and Asia-Pacific — collectively representing over 90% of global spending on stroke treatment devices and cerebrovascular intervention tools.

### North America

| Country | Key Metric | Key Driver |
| --- | --- | --- |
| United States | 82% of regional share | Medicare stenting expansion, comprehensive stroke center density |
| Canada | 7.68% CAGR | Provincial stroke-network standardization |
| Mexico | USD 0.09 Billion | IMSS public-hospital neurovascular procurement |

The United States alone accounts for more than 80% of North American spending on endovascular [neurology devices](https://www.marketresearchfuture.com/reports/neurology-devices-market-9768), propelled by over 1,800 Joint Commission-certified stroke centers and aggressive payer coverage for mechanical thrombectomy. Canada's provincial health authorities are harmonizing stroke treatment protocols modeled on U.S. AHA/ASA guidelines, while Mexico's IMSS system is piloting neurovascular device procurement at 12 tertiary referral hospitals under a 2024 infrastructure modernization initiative [4].

### Europe

| Country | Key Metric | Key Driver |
| --- | --- | --- |
| Germany | 28% of the regional share | DRG reimbursement for thrombectomy |
| United Kingdom | 7.85% CAGR | NHS mechanical thrombectomy rollout |
| France | USD 0.18 Billion | Plan AVC national stroke strategy |
| Italy | 7.52% CAGR | Regional stroke network integration |
| Spain | USD 0.11 Billion | ICTUS registry-driven adoption |
| Nordic Countries | 8.02% CAGR | High per-capita healthcare spending |
| Russia | USD 0.06 Billion | Federal cardiology center upgrades |
| Rest of Europe | 12% of regional share | Mixed adoption timelines |

Germany leads European adoption of cerebrovascular intervention tools, supported by DRG reimbursement codes that fully cover thrombectomy procedures. The UK's NHS has committed to making mechanical thrombectomy available in every integrated stroke delivery network by 2027, which will require significant procurement of stroke treatment devices across 24 designated thrombectomy hubs [7].

### Asia-Pacific

| Country | Key Metric | Key Driver |
| --- | --- | --- |
| China | 38% of regional share | 14th Five-Year Plan stroke infrastructure |
| India | 10.15% CAGR | National NCD programme, greenfield hospitals |
| Japan | USD 0.21 Billion | NHI expanded indications for endovascular devices |
| South Korea | 8.74% CAGR | NHIS cerebrovascular reimbursement reform |
| ASEAN | USD 0.08 Billion | Medical-tourism hub development |
| Rest of Asia-Pacific | 7.96% CAGR | Early-stage market penetration |

China's dominance within the Asia-Pacific Neurovascular Devices Market rests on aggressive public-hospital capital programs and the localization strategies of multinational device firms, including Medtronic and MicroPort. India represents the fastest-growing country opportunity, where the rising metabolic burden of hypertension and diabetes drives stroke incidence upward at approximately 4.5% annually, creating sustained demand for aneurysm coiling equipment and intracranial stent systems [6][12].

### South America

| Country | Key Metric | Key Driver |
| --- | --- | --- |
| Brazil | 62% of regional share | SUS public-health procurement |
| Argentina | 7.18% CAGR | Private-hospital neurovascular investment |
| Rest of South America | USD 0.04 Billion | Early-stage adoption |

Brazil's Unified Health System (SUS) remains the primary procurement channel for stroke treatment devices in the region, though lengthy tender cycles and currency volatility continue to moderate growth. Argentine private hospitals are investing in catheter laboratories equipped for cerebrovascular intervention tools, partially offsetting macroeconomic headwinds.

### Middle East & Africa

| Country | Key Metric | Key Driver |
| --- | --- | --- |
| Saudi Arabia | 32% of regional share | Vision 2030 healthcare expansion |
| UAE | 8.63% CAGR | Medical tourism and JCI-accredited stroke centers |
| South Africa | USD 0.03 Billion | Private-sector Netcare and Life Healthcare investment |
| Egypt | 7.55% CAGR | Public-hospital neurology upgrades |
| Rest of MEA | USD 0.02 Billion | Early-stage infrastructure |

Saudi Arabia's Vision 2030 strategy has channeled over USD 65 billion into healthcare infrastructure, including dedicated neuroscience centers in Riyadh and Jeddah that are procuring endovascular neurology devices at scale. The UAE's medical-tourism ecosystem drives advanced stroke treatment device adoption, with JCI-accredited hospitals in Dubai and Abu Dhabi treating a growing share of international stroke patients.

## Competitive Benchmarking

The Neurovascular Devices Market exhibits medium concentration, with the top five players holding an estimated 62–68% combined share. The Herfindahl-Hirschman Index sits in the 1,200–1,500 range, characteristic of an oligopolistic structure where three global medtech firms compete against a cadre of specialized neurovascular pure-plays. Competitive intensity is rising as aspiration catheter efficacy data narrows the performance gap between market leaders and challengers.

| Company | Est. Revenue Share Range | Key Offerings for the Neurovascular Devices Market | Strategic Positioning |
| --- | --- | --- | --- |
| Medtronic plc | ~18–22% | Pipeline Flex embolization, Solitaire X stent retriever | Broadest portfolio across stroke treatment devices and flow diverters |
| Stryker Corporation | ~15–19% | Trevo NXT thrombectomy, Surpass Streamline flow diverter | Thrombectomy leadership, robotic-assisted pipeline |
| Penumbra Inc. | ~9–12% | Lightning aspiration system, SMART PACK coils | Aspiration-first strategy with AI-guided catheter R&D |
| MicroVention (Terumo) | ~8–11% | FRED flow diverter, Headway micro-catheters | Flow-diverter innovation, strong Asia-Pacific distribution |
| Johnson & Johnson (Cerenovus) | ~6–9% | EMBOTRAP III stent retriever, Cascade micro-platform | Leveraging J&J's global distribution for cerebrovascular intervention tools |
| Balt Group | ~3–5% | SILK+ flow diverter, Squid liquid embolic | European niche leader in aneurysm coiling equipment |
| Phenox GmbH | ~2–4% | pREset thrombectomy, CHS Cranial hemostasis | Innovation-driven pure-play focused on endovascular neurology devices |
| MicroPort Scientific | ~2–4% | Tubridge flow diverter, NUMEN stent retriever | Chinese domestic champion with an emerging export strategy |
| Acandis GmbH | ~1–3% | DERIVO flow diverter, APERIO thrombectomy | German engineering focus, intracranial stent systems specialization |
| Wallaby Medical | ~1–2% | Avenir aspiration catheter, EmboTrap competitor | Fast-growing Chinese challenger in aspiration technology |

## Recent News & Developments

- [Medtronic plc](https://www.medtronic.com/en-us/healthcare-professionals/products/neurological/neurovascular.html) (January 2025): Medtronic and Contego Medical signed an exclusive US distribution agreement for the Neuroguard IEP integrated stent-balloon-filter platform.
- Q'Apel Medical (January 2025): Q'Apel Medical obtained the Armadillo CE mark. The neurovascular access system SelectFlex 7F.

## Report Scope

| Parameter | Detail |
| --- | --- |
| Market Scope | Global Neurovascular Devices Market across product types, target diseases, end users, and 5 regions (42 countries) |
| Study Period | 2021–2035 |
| CAGR | 8.22% (2026–2035) |
| Market Size — Base Year (2025) | USD 5.17 Billion |
| Market Size — Forecast End (2035) | USD 10.48 Billion |
| Fastest Growing Segment (Product) | Neurothrombectomy Devices (9.14% CAGR) |
| Fastest Growing Region | Asia-Pacific (9.28% CAGR) |
| Companies Profiled | 10 (Medtronic, Stryker, Penumbra, MicroVention, J&J Cerenovus, Balt, Phenox, MicroPort, Acandis, Wallaby Medical) |
| Valuation Currency | USD Billion |

## Frequently Asked Questions

**Q: How does the performance gap between stent retrievers and aspiration catheters influence procurement decisions in the Neurovascular Devices Market?**
A: Recent RCTs show comparable TICI 2b/3 recanalization rates (~87%) for both approaches, making operator preference and catheter-lab workflow the decisive procurement factors [2]. Most hospitals now stock both device types to allow case-by-case selection.

**Q: What training infrastructure exists for hospitals adopting robotic-assisted cerebrovascular intervention tools?**
A: Manufacturers offer 3–5 day proctored training programs combining cadaver simulation, virtual-reality modules, and live-case observation [5]. Board certification bodies are developing robotic endorsement credentials expected by 2028.

**Q: How do biodegradable intracranial stent systems compare to permanent metallic flow diverters in long-term outcomes?**
A: Early-phase trials show bioresorbable scaffolds achieve vessel remodeling within 18 months, eliminating lifelong dual-antiplatelet therapy requirements [17]. Pivotal data from larger randomized trials is anticipated by 2029.

**Q: What role does the Neurovascular Devices Market play in addressing stroke disparities in rural communities?**
A: Tele-stroke networks paired with mobile catheter-lab units are extending endovascular neurology device access to rural areas [14]. These models reduce treatment delays by enabling remote specialist guidance during acute interventions.

**Q: How are warranty and service-contract structures evolving for high-value aneurysm coiling equipment?**
A: Manufacturers are shifting toward outcome-linked contracts where service fees are tied to device uptime and procedural throughput benchmarks [16]. This model aligns vendor incentives with hospital operational efficiency.

**Q: What cybersecurity risks accompany networked stroke treatment devices in hospital environments?**
A: Connected catheter navigation platforms and AI triage systems introduce endpoint vulnerabilities requiring FDA-mandated Software Bill of Materials compliance [10]. Hospitals increasingly require IEC 62443 certification from device vendors.

**Q: How does the Neurovascular Devices Market respond to sudden spikes in hemorrhagic stroke incidence following anticoagulant therapy trends?**
A: Rising DOAC prescriptions have modestly increased hemorrhagic conversion risk, driving incremental demand for embolization devices and endovascular neurology devices designed for hemorrhagic management [12]. Device makers are developing coils optimized for anticoagulated patients.


## Sources

[2] Source: American Heart Association, "2024 Guidelines for Early Management of Acute Ischemic Stroke," Stroke, 2024 (www.ahajournals.org)
[4] Source: Centers for Medicare & Medicaid Services, "CY2024 OPPS Final Rule — Carotid Stenting Coverage," CMS, 2024 (www.cms.gov)
[5] Source: Siemens Healthineers, "Corindus Robotic-Assisted Neurovascular Procedures — Clinical Outcomes," 2024 (www.siemens-healthineers.com)
[6] Source: Ministry of Health and Family Welfare (India), "NPNCD Phase IV — Stroke Infrastructure Allocation," Government of India, 2024 (mohfw.gov.in)
[7] Source: European Commission, "EU MDR Implementation — Notified Body Capacity Report," DG GROW, 2024 (ec.europa.eu)
[8] Source: Ambulatory Surgery Center Association, "2024 ASC Procedure Volume Report — Neurovascular Trends," ASCA, 2024 (www.ascassociation.org)
[9] Source: Viz.ai, "AI-Powered Stroke Detection — Clinical Impact Data," Viz.ai White Paper, 2024 (www.viz.ai)
[12] Source: World Health Organization, "Global Stroke Action Plan 2023–2030," WHO, 2023 (www.who.int)
[13] Source: ECRI Institute, "Capital Equipment Planning — Biplane Neuro-Angiography Suites," ECRI, 2024 (www.ecri.org)
[14] Source: Society of NeuroInterventional Surgery, "2024 Workforce Survey — Global Neuro-Interventionalist Supply," SNIS, 2024 (www.snisonline.org)
[16] Source: Medtronic plc, "Annual Report FY2024 — Neurovascular Division Performance," Medtronic, 2024 (investorrelations.medtronic.com)
[17] Source: MicroVention Inc., "PREMIER Trial — 3-Year FRED Flow Diverter Outcomes," Journal of NeuroInterventional Surgery, 2024 (jnis.bmj.com)
[18] Source: European Commission, "Corporate Sustainability Reporting Directive (CSRD) — Implementation Guidance," DG FISMA, 2025 (ec.europa.eu)

---

*This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/neurovascular-devices-market-5544*